Lifeboat Foundation

Personalized regenerative medicine company Aspen Neuroscience has joined forces with Emerald Innovations and Rune Labs to integrate digital health monitoring technology into its Trial Ready Screening Cohort Study. The study, which began in 2022, seeks to identify potential patient candidates for a future clinical trial of Aspen’s personalized cell therapy (ANPD001) in Parkinson’s disease.

Aspen’s approach targets Parkinson’s disease by replenishing lost dopamine neurons, addressing both motor and non-motor symptoms of the disease. By combining cutting-edge biosensors, software analytics, and cellular therapies, the new collaboration aims to significantly improve the quality of life for those living with Parkinson’s disease.

Harnessing the capabilities of Emerald Innovations’ ‘invisible’ off-body sensors and Rune Labs’ precision neurology software, Aspen intends to bolster the collection of objective measures of motor function. The company says the partnership will enable long-term symptom capture, providing useful data on disease progression before treatment.

Tardigrades have been frozen, boiled, exposed to extreme doses of radiation, and remarkably still survive. How?

Hypotension is a common complication during general anesthesia associated with increased postoperative mortality and morbidity. Every episode of intraoperative hypotension, regardless of duration, is linked to the risk of acute kidney injury and cardiovascular events. The vulnerability to hemodynamic disturbances increases with age, underscoring the need for prompt interventions for elderly patients who experience hypotension during anaesthesia.

Using ephedrine resulted in a notable rise in mean arterial pressure (MAP) and cardiac output (CO). Still, no meaningful correlation with age was detected in patients aged 45 years or older. These results imply that ephedrine is reliable for managing low blood pressure during general anaesthesia, even in elderly patients, says Yuta Uemura in a recent study published in BMC Anesthesiology.

Ephedrine is a mixed α- and β-agonist vasopressor for correcting hypotension during general anaesthesia. β-responsiveness decreases with age; therefore, this study aimed to determine whether ageing would reduce the pressor effect of ephedrine on hypotension during general anaesthesia.

Scientists have found a way to reprogram human cells so that they mimic the highly plastic embryonic stem cells that have so much promise for use in regenerative medicine. By essentially wiping the cell’s “memory”, the team have created so-called induced pluripotent stem (iPS) cells, which could be used to regenerate or repair diseased tissue and organs.

IPS cells are a type of pluripotent cell that can be obtained by reprogramming mature human adult cells (“somatic” cells) into an embryonic stem cell-like state. This means that they have the capacity to differentiate into any cell of the body. They were first demonstrated in 2006, and have myriad potential biomedical and therapeutic uses, including disease modeling, drug screening, and cell-based therapies.

Despite this promise, researchers have continually hit a stumbling block that has prevented iPS cells from realizing their potential. “A persistent problem with the conventional reprograming process is that iPS cells can retain an epigenetic memory of their original somatic state, as well as other epigenetic abnormalities,” Professor Ryan Lister, lead author of a paper presenting the latest breakthrough, said in a statement.

After decades of research the potential of regenerative medicine becomes a life-saving reality.

Renewing the aging gut microbiome holds promise for preventing inflammatory brain and eye degeneration.

In this video, we’ll dive deep into the cutting-edge research on how Artificial Intelligence (AI) and Artificial General Intelligence (AGI) are helping us to better understand the aging process and unlock the secrets to living forever.

We’ll discuss the latest breakthroughs in AI and AGI and how they are enabling researchers to analyze vast amounts of data, identify patterns, and make predictions that were once impossible. We’ll also explore how AI and AGI are being used to develop new treatments and therapies to prevent or reverse aging-related diseases within the Longevity Industry.

This is according to a report by Euronews Next published on Saturday.

A major discovery

Dr Andreas Beyer, the lead researcher, told the news outlet this is a “major discovery.”

The successful transfer of a gene that produces HMW-HA paves the way for improving the health and lifespan of humans, too. In a groundbreaking endeavor, scientists at the University of Rochester have successfully transferred a longevity gene from naked mole rats to mice, leading to enhanced health and increased lifespan. Naked mole rats, noted for their resistance to age-related diseases, have a gene that produces high molecular weight hyaluronic acid (HMW-HA), which when introduced to mice, demonstrated potential anti-aging benefits.